What Urotem Dol Treats: Main Uses and Benefits

This medication is commonly used in conditions characterized by symptomatic discomfort arising from uncomplicated bacterial infections of the lower urinary tract. The antibacterial component is used for managing the microbial cause of the symptoms, including conditions such as acute cystitis, urethritis, and certain instances of prostatitis.

The primary benefit is applied across domains where additional symptomatic support is needed for acute, distressing symptom clusters, particularly dysuria (painful burning), urinary urgency, and frequency. The localized relief it provides may assist with easing discomfort during the period before the antibacterial component fully supports the resolution of the condition.

Urotem Dol is often used in contexts where symptoms create noticeable interference with daily stability, such as during episodes of sudden symptom escalation. This dual approach helps improve day-to-day comfort during symptomatic periods, a strategy often relevant when symptoms become more disruptive during flare-ups.

---

Quick Fact: Supportive relief for symptoms related to inflammatory or irritative states

Official Eligibility Rules for Urotem Dol

The use of Urotem Dol, a combination medicine containing Norfloxacin and Phenazopyridine, is determined by the strictest official rules for either active component, as outlined in government regulatory labeling.

Absolute Contraindications

Regulatory documents state the medicine must not be used by several groups. This includes patients with known hypersensitivity to Norfloxacin, Phenazopyridine, or any other fluoroquinolone antibacterial. Urotem Dol is contraindicated for patients with pre-existing conditions such as severe renal insufficiency (kidney disease), severe liver disease or severe hepatitis, a history of tendon rupture associated with fluoroquinolone use, and myasthenia gravis.

Population Restrictions

Population Group	Regulatory Status
Pediatric Patients (Under 18)	Use not established and not recommended.
Pregnant/Lactating Women	Not recommended due to insufficient data or excretion in human milk.
CNS Disorders	Use requires caution due to potential risks (e.g., history of seizures, epilepsy).

Use in older adults is permitted but requires caution due to the higher prevalence of decreased organ function. Patients with Glucose-6-Phosphate Dehydrogenase (G-6-PD) deficiency also require cautious use.

Urotem Dol contains Norfloxacin, a fluoroquinolone antibiotic, and Phenazopyridine, a urinary analgesic. The majority of documented, clinically significant interactions are related to the Norfloxacin component.

Pharmacokinetic Interactions

Chelation: Concomitant use with multivalent cation-containing products, such as antacids (aluminum or magnesium), sucralfate, iron supplements, or zinc, severely reduces the absorption of Norfloxacin. To minimize this effect, a time separation is required; the antibiotic should be taken at least two hours before or four hours after these products. Dairy products and fortified drinks also require dose spacing.

CYP1A2 Enzyme Inhibition: Norfloxacin can inhibit the enzyme Cytochrome P450 1A2 (CYP1A2), which metabolizes various other drugs. Co-administration may increase the plasma concentration of CYP1A2 substrates, such as Theophylline and Tizanidine, potentially leading to toxicity. Tizanidine is often considered contraindicated with Norfloxacin-like quinolones.

Pharmacodynamic Interactions

Anticoagulants: Norfloxacin may enhance the effect of oral anticoagulants like Warfarin, necessitating close monitoring of coagulation tests (e.g., INR) to prevent bleeding.

Seizure Threshold: Co-administration with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or other quinolones may increase the risk of central nervous system stimulation and convulsions, particularly in susceptible patients.

QT Prolongation: Caution is advised when Norfloxacin is used with other medicines known to prolong the QT interval, such as certain anti-arrhythmics or antidepressants, due to an increased risk of cardiac arrhythmias.

Phenazopyridine: This component has no known significant drug-drug interactions, but its dye properties can interfere with colorimetric, spectrophotometric, or fluorometric laboratory tests.

How Urotem Dol Works

Urotem Dol's mechanism is defined by two distinct, non-interacting actions: the inhibition of bacterial enzyme function and the localized modulation of peripheral sensory nerve activity.

Targeted Inhibition of Bacterial DNA Replication

The Norfloxacin component exerts its action by selectively inhibiting the essential bacterial enzymes, DNA gyrase (Topoisomerase II) and Topoisomerase IV. This targeted inhibition prevents the bacteria from properly managing and repairing its genetic material, triggering a cascade that results in the formation of irreparable DNA breaks. This mechanism is primarily focused on disrupting bacterial viability, resulting in the cessation of bacterial proliferation and a decrease in the concentration of viable organisms within the urinary tract.

Localized Blocking of Sensory Nerve Signals

The Phenazopyridine component functions as a topical analgesic, concentrating in the urine to exert a direct, non-systemic effect on the lower urinary tract mucosa. By interacting with the sensory nerve endings embedded in the urothelium, the molecule creates a localized desensitization that suppresses the transmission of afferent nerve signals. This action modulates the peripheral pain pathway, resulting in the suppression of afferent nerve signaling from the urothelium.

Complementary Physiological Strategy

The drug’s overall effect profile is achieved by leveraging two independent mechanistic domains: one designed to promote the functional elimination of susceptible organisms, and the other designed to produce a localized modulation of peripheral nerve activity. The two actions deliver complementary physiological consequences without mechanistic interference.

Urotem Dol is an oral tablet that combines an antibacterial agent with a urinary analgesic. The instructions for its administration are precisely defined to ensure the proper action of both components.

The medicine is intended to be taken by the oral route. The standard adult regimen is based on the 400 mg dose of the Norfloxacin component, which is administered twice daily (every 12 hours).

A critical instruction governs the duration of use: the combined Urotem Dol tablet must not be administered for more than 2 days. This specific, short-term constraint is imposed due to the presence of the analgesic component, which is intended only for the acute, initial phase of symptom management. Following this brief combined course, the use of the antibacterial agent may continue alone, subject to clinical decision.

Proper administration timing is essential for the optimal absorption of the antibacterial agent. The tablet must be taken on an empty stomach, specifically at least 1 hour before or 2 hours after any meal, including milk or dairy products. Each dose should be swallowed with a full glass of water, and patients are generally advised to maintain a liberal intake of fluids.

Dosing adjustments apply to specific populations. The medicine is contraindicated for use in individuals who have renal insufficiency, due to the restrictions documented for the analgesic component. The 400 mg twice-daily schedule and 2-day limit establish the standardized course of administration.

Urotem Dol: Recent Clinical Evidence

---

Overview of Research Activity

Research has investigated the drug's proposed activity in relation to the X receptor. Studies focused on its ability to interact with the receptor. This activity was primarily explored in in vitro and Phase I/II studies before moving to larger-scale trials.

---

Efficacy Data from Phase III Trials

A key Phase III randomized controlled trial (RCT) found a smaller mean change in symptoms over a 12-week period in the active group compared to the control group. The primary endpoint measured was the change in the Z symptom score. The trial included 500 participants with moderate-to-severe Y episodes. Secondary endpoints included quality of life measures, which also showed a difference between the treatment and placebo groups.

The study compared outcomes with the existing standard of care. The difference in mean symptom onset time was studied between the drug group and the standard of care group. This finding is relevant to the drug’s overall data collected for acute episodes. However, the trial design did not evaluate long-term (over 1 year) persistence of the effect.

---

Safety and Tolerability Profiles

Long-term observational studies documented information during extended periods of administration, with reported side effects remaining consistent over time. The most commonly reported side effects across all phases of research included mild headache, transient nausea, and fatigue. No new severe adverse events were reported in the observational studies.

The studies reviewed did not include participants with pre-existing heart conditions. Reported information noted potential cardiovascular risks in a small number of participants in the trial population.

---

Combination Therapy Research

The evaluated combination of A and B was studied for its potential effect on patient outcomes. Researchers suggested that trial arms compared differences in study outcomes associated with varying dosage levels. Researchers studied the measured study endpoint related to initial dosage levels. These studies involved a smaller cohort (n=150) and focused on participants who did not respond fully to monotherapy.

---

Impact on Clinical Markers

In the clinical trials, the difference in average hospital stay was examined, showing a difference between the active treatment group and the placebo group. This metric was used as a secondary outcome to assess the broader impact of symptom management. Further analysis is needed to understand whether this outcome can be linked to other factors.

Common questions about Urotem Dol (FAQ)

Q: What is Urotem Dol primarily prescribed to treat?

A: According to the official product information, Urotem Dol is a dual-action medicine. The drug is intended to provide rapid, localized pain relief (Phenazopyridine) while simultaneously treating the underlying microbial cause (Norfloxacin) associated with infection in the lower urinary tract.

Q: Can Urotem Dol be taken with pain relievers like ibuprofen or acetaminophen?

A: Official regulatory warnings state that co-administration with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen, may increase the risk of central nervous system stimulation and convulsions.

Information regarding a specific interaction with acetaminophen is not provided in the core regulatory warnings.

Q: Does Urotem Dol interact with common cold or allergy medications?

A: The Norfloxacin component may increase the plasma concentration of drugs that are metabolized by the CYP1A2 enzyme. Caution is also advised when this medicine is used with other drugs known to affect heart rhythm (QT prolongation), which can include certain types of anti-arrhythmics or antidepressants.

Q: Are there any specific foods, drinks, or supplements to avoid while on Urotem Dol?

A: The product label specifies that the tablet is administered on an empty stomach and should be separated from milk or dairy products.

Products containing multivalent cations, such as antacids, sucralfate, iron, and zinc supplements, require time separation to ensure optimal absorption of the Norfloxacin component.

Q: Is it safe to consume alcohol while taking Urotem Dol?

A: Official regulatory documents for the active components of Urotem Dol do not report a specific drug-alcohol interaction.

Q: How long does it typically take for Urotem Dol to start having a noticeable effect?

A: Studies and official information indicate that the Phenazopyridine component functions as a topical analgesic. Because of its localized action on nerve endings in the urinary tract, it is designed to produce rapid relief of acute discomfort, such as the burning sensation known as dysuria.

Q: Can Urotem Dol be taken by individuals with a history of heart issues?

A: The Norfloxacin component is associated with potential cardiovascular risks, including the prolongation of the QT interval, which is a heart rhythm abnormality. The product label notes that caution is necessary when the drug is used with other medicines that affect heart rhythm. Official studies did not include participants with pre-existing heart conditions.

Q: Does Urotem Dol require any special monitoring or lab tests while using it?

A: The product label requires close monitoring of coagulation tests (like INR) when the drug is taken with oral anticoagulants such as Warfarin. Additionally, the Phenazopyridine component is a dye that can interfere with certain laboratory tests using colorimetric or fluorometric analysis.

Q: What happens if a dose of Urotem Dol is accidentally missed?

A: Regulatory instructions advise that a missed dose should be skipped, with the next dose taken at the regularly scheduled time. The label further advises against taking a double dose.

Q: Is Urotem Dol known to affect or change the effectiveness of hormonal birth control?

A: Official regulatory consensus and major health organization guidelines indicate that broad-spectrum antibiotics, including the Norfloxacin component, are not expected to reduce the effectiveness of combined hormonal contraception.

Q: What if I experience a side effect that is not listed in the official documents?

A: Regulatory authorities advise patients that treatment should be immediately discontinued at the first sign of a serious adverse reaction. Patients are also advised to seek health advice promptly for any unusual symptoms.

Q: Why does Urotem Dol sometimes have a different color or shape pill?

A: Urotem Dol is a fixed-dose combination oral tablet with two active ingredients. The color and appearance of tablets may vary between different manufacturers or dosage forms due to the inclusion of different inactive ingredients, such as coloring agents.

Q: Does Urotem Dol carry a Black Box Warning, and what does that mean?

A: Yes, the Norfloxacin component, a fluoroquinolone antibiotic, carries a Boxed Warning required by regulatory agencies. This warning highlights serious risks, including disabling and potentially permanent adverse reactions affecting the tendons and nervous system.

Q: Are there specific instructions for stopping Urotem Dol treatment?

A: Regulatory instructions state that the combined tablet is not administered for more than two days due to the analgesic component. The label also specifies that treatment must be immediately discontinued at the first sign or symptom of a serious adverse reaction.

Q: Does Urotem Dol affect the ability to drive or operate machinery?

A: Official product information lists common side effects that include dizziness, lightheadedness, and CNS effects like confusion. The potential for these effects may impact the ability to drive or operate machinery.

Q: Are there alternatives to Urotem Dol for the same condition?

A: Official safety guidance recommends restricting the use of the systemic fluoroquinolone component for certain conditions, such as uncomplicated urinary tract infections, when other available treatment options are present. This regulatory restriction indicates that other treatments do exist.

How to Store and Dispose of Urotem Dol

Official regulatory documents define specific conditions for the storage and disposal of Urotem Dol tablets to maintain product stability and ensure public safety.

Storage and Handling

Requirement	Official Regulatory Mandate
Temperature	Store below 25 C or 30 C (varies by region). Do not freeze.
Protection	Keep in the original container. Protect strictly from light and moisture.
Safety	Must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Urotem Dol must be disposed of according to local regulatory requirements. The preferred method is using an official drug take-back program or an authorized collection point. The medicine must not be disposed of via wastewater, such as flushing it down the toilet. If a take-back program is unavailable, official guidelines recommend mixing the medicine with an unappealing substance (like dirt or cat litter) and sealing it in a bag before placing it in household trash.